drugset / Trial / NCT06047262
Dapansutrile in Diabetes and Diabetes-Related Complications - Dapan-Dia
Phase 2
Recruiting
300 enrolled
Marc Donath
CTU Kantonsspital Baden · collabDepartement Klinische Forschung Universität Basel · collabEuropean Union (Horizon Europe Programme) · collabOlatec Therapeutics, Inc. · collabState Secretariat for Education Research and Innovation, Switzerland · collab
RandomizedParallel-groupDouble-blindTreatment
Summary
The aim of the study is to determine whether NLRP3 inhibition with dapansutrile represents a new pharmacological option for diabetes management with potential as an anti-inflammatory agent to also address micro- and macro-vascular risk and complications from diabetes.
Timeline
- Start
- 2024-07-09
- Primary completion
- 2028-07-31
- Completion
- 2028-07-31
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Dapansutrile | Small molecule | 1000 mg | Oral |